Madrid

• International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies … Recruiting
  2022-501869-41-00 9 2023-11-14 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• FOENIX-CCA4 Recruiting
  2023-503665-39-00 4 2023-11-14 Advanced cholangiocarcinoma
• A study to assess efficacy of citicoline on visual field preservation in patients with glaucoma Recruiting
  2022-502273-42-00 5 2023-11-08 Glaucoma
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• Safety, pharmacokinetics, and preliminary efficacy of VIR-5500 (AMX-500) in prostate cancer Recruiting
  2023-503495-24-00 1 2023-10-30 Hormone-refractory prostate cancer
• 177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting
  2022-502154-13-00 5 2023-10-27 Patients with well to moderately differentiated neuroendocrine tumors
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• A Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center study of rotigotine in com … Recruiting
  2023-504602-11-00 5 2023-10-25 Mild to moderate Alzheimer's disease
• Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER) Recruiting
  2022-502060-21-00 6 2023-10-19 Haemophilia A
• Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan. Recruiting
  2023-505385-28-00 4 2023-10-19 male or pre/post-menopausal women age ≥ 18 years with locally advanced
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons with Severe or Moderate … Recruiting
  2023-503906-35-00 9 2023-10-11 Severe or Moderate Hemophilia A with or without factor VIII inhibitors
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting
  2023-510541-25-00 1 2023-10-09 Relapsed/Refractory B-cell Malignancies
• A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination … Recruiting
  2023-504845-30-00 7 2023-10-05 Solid malignancies
• Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Recruiting
  2024-518844-20-00 10 2023-10-03 Treatment of Acute Gout Flare
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting
  2022-502160-20-00 5 2023-10-02 Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting
  2022-502281-25-00 5 2023-09-27 Focal Onset Seizures
• A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To … Recruiting
  2022-502357-34-00 5 2023-09-27 Extensive Stage Small Cell Lung Cancer
• Multicenter, controlled, randomized, observer-blinded clinical trial to evaluate the efficacy and safety of insulin eye drops (1 IU/ml) in t … Recruiting
  2024-518818-53-00 5 2023-09-26 Persistent corneal epithelial defect.
• Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment resp … Recruiting
  2023-506165-62-00 6 2023-09-25 Atopic dermatitis
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• A Dose Escalation and Expansion Study of BGB-16673 in Patients with B Cell Malignancies Recruiting
  2022-502157-33-00 7 2023-09-18 B-Cell Malignancies
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given with Either Cemiplimab, or Cemiplimab + Fianlimab, … Recruiting
  2022-501904-83-00 7 2023-09-11 Ovarian Cancer
• Phase II, multicenter, randomized, open-label study of premenopausal women with luminal breast cancer investigating the effect of elacestran … Recruiting
  2023-503373-37-01 4 2023-09-11 Premenopausal women with early luminal breast cancer

Showing 1,441–1,464 of 3,550 trials